

Product Data Sheet

Product Name: F 16915
Cat. No.: GC34039

Chemical Properties

Cas. No. 92510-91-3

SMILES CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(OCC1=CC=CN=C1)=O


Formula $C_{28}H_{37}NO_2$ M.Wt 419.6

Solubility DMSO : ≥ 100 mg/mL (238.32 mM) Storage $-20^{\circ}C$, protect from light

General tips For obtaining a higher solubility , please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Protocol

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Animal experiment: Male Sprague-Dawley rats weighing 220 to 300 g are used in this study. The rats are anesthetized using isoflurane 3% on O₂. Then, the animals are intubated and ventilated at 60 respirations/min (2.5 mL/respiration) while anesthesia is maintained. A left thoracotomy is performed, and a silk suture is placed around the left coronary artery ~1 mm from its origin. The treatment starts just after the surgery. A single administration of 100 mg/kg F 16915 or vehicle (olive oil) is daily administrated orally by force-feeding[1].

References:

[1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77.

Background

F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation.

F 16915 is a docosahexaenoic acid derivative which can prevent heart failure-induced atrial fibrillation. Time-dependent changes in blood concentrations of total docosahexaenoic acid (DHA) and nicotiny alcohol are followed after a single oral administration of F 16915 (300 mg/kg) to male rats. Treatment with F 16915 has no significant effect on body weight: 27.7±2.9 kg and 28.1±1.0 kg before surgery versus 29.2±3.4 kg and 28.8±1.7 kg after in the 1 and 5 g/day groups, respectively. F 16915 administered at 5 g/day for 4 weeks significantly reduces the mean duration of Atrial fibrillation (AF) induced by burst pacing but has no significant effect at 1 g/day. The duration of AF is significantly reduced from 989±111 s in the placebo group to 79±59 s in the presence of F 16915 at 5 g/day. Treatment of 2 months with 100 mg/kg F 16915 also significantly reduces the infarct size[1].

[1]. Le Grand B, et al. F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):667-77.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA